Celularity to serve as the exclusive partner for the finish manufacturing of Vesalius’s Peptual peptide APIs, supporting Vesalius’s expansion into pharmaceutical ingredient supply
Collaboration advances Celularity’s
FLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced that it received written
FLORHAM PARK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering
FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative medicine company, today announced that Naveen Jain, founder and
Plan combines up to $25 million in new capital with restructuring of $3 million in existing debt to support commercial execution and manufacturing expansion Company anticipates positive monthly operating cash flow by
Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa
FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company") today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications
FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular
FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that it received a notification letter
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that it has filed its
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the
Transaction expected to approximately triple NEXGEL's annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified suite of 6 established
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously
